Form 4: PBH Director John Kelly Receives RSU Grant

Prestige Consumer Healthcare Inc. director John F. Kelly was granted 2,094 restricted stock units valued at $155,000 as part of the company's director compensation program.

Summary

• Director John F. Kelly of Prestige Consumer Healthcare Inc. (PBH) received a grant of 2,094 restricted stock units (RSUs).
• The value of this RSU grant was $155,000, calculated based on the closing stock price of $74.04 on August 5, 2025.
• This grant is part of the Issuer's standard director compensation program.
• The RSUs are scheduled to vest on the first anniversary of the grant date.
• Settlement of the vested RSUs will occur upon the earliest of Mr. Kelly's death, separation from the company, or a change in control.
• Following this transaction, Mr. Kelly beneficially owns 4,851 shares of common stock directly.

Sentiment

Score: 6

Explanation: The filing reports a routine equity compensation grant to a director, which is a neutral to slightly positive event as it aligns director interests with shareholders. It does not indicate any significant positive or negative operational or financial news.

Positives

• The grant of restricted stock units aligns the director's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• It indicates a standard, ongoing compensation practice for directors, reflecting stable corporate governance.

Future Outlook

This filing does not contain forward-looking statements or guidance beyond the vesting and settlement terms of the granted restricted stock units.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across various industries, including consumer healthcare, to align executive and director incentives with shareholder interests. It does not provide broader industry trends or competitive insights.

Comparison to Industry Standards

• The grant of restricted stock units as part of director compensation is a standard practice in publicly traded companies, including those in the consumer healthcare sector.
• While specific compensation amounts vary by company size and industry, the mechanism of equity-based awards like RSUs is widely adopted to foster long-term alignment.
• No specific comparable companies or projects are mentioned in this filing to allow for a detailed comparative assessment of the compensation amount.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders, potentially encouraging decisions that enhance long-term stock value.

Next Steps

• The granted restricted stock units are scheduled to vest on August 5, 2026.
• Settlement of the vested RSUs will occur upon the earliest of the Reporting Person's death, separation from the company, or a change in control.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to an existing director. It does not provide new material information regarding the company's financial performance, strategic direction, or operational outlook that would warrant a change in investment recommendation. The transaction is a standard part of director compensation and aligns the director's interests with shareholders, which is a neutral to slightly positive factor, but not enough to change a fundamental investment thesis.

Keywords

Prestige Consumer Healthcare, PBH, John F. Kelly, Director Compensation, Restricted Stock Units, RSU Grant, Insider Transaction, SEC Form 4, Equity Compensation